The Food and Drug Administration today announced four priority areas for additional policy activity in 2018: reducing addiction to opioid drugs and cigarettes; promoting innovation and competition; empowering consumers to make informed decisions; and strengthening the FDA workforce. Specific policy efforts include new steps to support and streamline development and approval of treatments that address addiction; reducing burdens for creating and approving generic drugs; and extending new hiring and pay authorities to recruit and retain FDA staff.

Related News Articles

Chairperson's File
During Mental Health Month, let’s all remember that caring for the whole person improves health and saves lives.
Headline
The Health Resources and Services Administration yesterday awarded 120 organizations, including hospitals, $200,000 each to develop community partnerships and…
Headline
As part of its efforts to promote behavioral health strategies, the AHA today released a TrendWatch report outlining the opportunities, barriers and solutions…
Insights and Analysis
AHA board member Harsh Trivedi is president and CEO of Sheppard Pratt Health System and is striving to improve health in the communities he serves across the…
Headline
Laws that allow pharmacists to dispense the opioid antidote naloxone without a physician’s prescription are associated with a sharp reduction in fatal opioid-…
Headline
The AHA today expressed support for bipartisan legislation that would expand access to treatment of mental illnesses and substance use disorders through…